First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Short Interest Update

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 35,896 shares, a growth of 73.5% from the June 30th total of 20,687 shares. Based on an average daily volume of 56,114 shares, the short-interest ratio is currently 0.6 days. Approximately 2.5% of the company’s stock are sold short.

First Trust Nasdaq Pharmaceuticals ETF Trading Down 0.9%

Shares of NASDAQ:FTXH opened at $38.93 on Friday. The stock has a fifty day simple moving average of $37.13 and a two-hundred day simple moving average of $35.24. The stock has a market capitalization of $873.98 million, a price-to-earnings ratio of 14.51 and a beta of 0.45. First Trust Nasdaq Pharmaceuticals ETF has a 12-month low of $25.76 and a 12-month high of $42.87.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, June 25th were issued a $0.092 dividend. This represents a $0.37 annualized dividend and a yield of 0.9%. This is a boost from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.06. The ex-dividend date of this dividend was Thursday, June 25th.

Hedge Funds Weigh In On First Trust Nasdaq Pharmaceuticals ETF

Hedge funds have recently bought and sold shares of the business. Vivaldi Capital Management LP raised its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 16.0% during the first quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock valued at $433,000 after purchasing an additional 1,741 shares during the last quarter. OLD Mission Capital LLC bought a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF during the 4th quarter valued at $528,000. Kestra Advisory Services LLC bought a new stake in First Trust Nasdaq Pharmaceuticals ETF during the fourth quarter valued at about $59,000. Commonwealth Equity Services LLC bought a new stake in First Trust Nasdaq Pharmaceuticals ETF during the 4th quarter valued at approximately $237,000. Finally, LPL Financial LLC raised its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 40.5% during the fourth quarter. LPL Financial LLC now owns 146,105 shares of the company’s stock valued at $4,813,000 after buying an additional 42,147 shares during the last quarter.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.